See more : Oxford Instruments plc (OXINF) Income Statement Analysis – Financial Results
Complete financial analysis of Kidpik Corp. (PIK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kidpik Corp., a leading company in the Specialty Retail industry within the Consumer Cyclical sector.
You may be interested
- Transaction Media Networks Inc. (5258.T) Income Statement Analysis – Financial Results
- Cypher Metaverse Inc. (BKLLF) Income Statement Analysis – Financial Results
- HORNBACH Holding AG & Co. KGaA (HBH3.SW) Income Statement Analysis – Financial Results
- Life Insurance Corporation of India (LICI.NS) Income Statement Analysis – Financial Results
- HEG Limited (HEG.BO) Income Statement Analysis – Financial Results
Kidpik Corp. (PIK)
About Kidpik Corp.
Kidpik Corp. operates as a subscription-based e-commerce company that sells kids apparel, footwear, and accessories. The company offers apparel, including tops, bottoms, cardigans, jackets, dresses, and swimwear in knit and woven fabrications; shoes, such as sneakers, boots, sandals, and dress shoes; and accessories comprising sunglasses, jewelry, bags, socks, hats, hair goods, and other items. It serves its customers through its retail website, shop.kidpik.com; amazon.com; and clothing subscription boxes, which provide mix-&-match coordinated outfits that are personalized based on each member's preferences. The company was incorporated in 2015 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 14.24M | 16.48M | 21.83M | 16.94M | 13.52M |
| Cost of Revenue | 8.23M | 6.60M | 8.84M | 7.05M | 5.28M |
| Gross Profit | 6.01M | 9.88M | 13.00M | 9.89M | 8.24M |
| Gross Profit Ratio | 42.22% | 59.95% | 59.53% | 58.39% | 60.97% |
| Research & Development | 0.00 | 0.00 | 0.00 | 21.76K | 50.21K |
| General & Administrative | 11.56M | 13.34M | 18.63M | 13.48M | 12.24M |
| Selling & Marketing | 0.00 | 7.40M | 9.24M | 6.86M | 6.63M |
| SG&A | 11.56M | 13.34M | 18.63M | 13.48M | 12.24M |
| Other Expenses | 4.36M | 4.36M | 26.91K | 72.84K | 100.40K |
| Operating Expenses | 15.92M | 17.70M | 18.66M | 13.56M | 12.34M |
| Cost & Expenses | 24.15M | 24.30M | 27.50M | 20.60M | 17.61M |
| Interest Income | 0.00 | 78.65K | 711.97K | 511.43K | 439.71K |
| Interest Expense | 686.00 | 78.65K | 711.97K | 511.43K | 439.71K |
| Depreciation & Amortization | 525.39K | 27.91K | 26.91K | 72.84K | 100.40K |
| EBITDA | -9.38M | -7.51M | -5.21M | -3.60M | -4.05M |
| EBITDA Ratio | -65.87% | -45.57% | -23.85% | -21.27% | -29.94% |
| Operating Income | -9.91M | -7.82M | -5.66M | -3.67M | -4.09M |
| Operating Income Ratio | -69.55% | -47.48% | -25.94% | -21.64% | -30.28% |
| Total Other Income/Expenses | -686.00 | 208.15K | -282.93K | -521.43K | -493.35K |
| Income Before Tax | -9.91M | -7.62M | -5.95M | -4.19M | -4.59M |
| Income Before Tax Ratio | -69.56% | -46.21% | -27.23% | -24.72% | -33.93% |
| Income Tax Expense | 0.00 | -208.15K | 1.33K | 1.12K | 15.97K |
| Net Income | -9.91M | -7.41M | -5.95M | -4.19M | -4.60M |
| Net Income Ratio | -69.56% | -44.95% | -27.24% | -24.73% | -34.05% |
| EPS | -6.04 | -4.83 | -3.90 | -2.75 | -3.02 |
| EPS Diluted | -6.04 | -4.83 | -3.90 | -2.75 | -3.02 |
| Weighted Avg Shares Out | 1.64M | 1.53M | 1.52M | 1.52M | 1.52M |
| Weighted Avg Shares Out (Dil) | 1.64M | 1.53M | 1.52M | 1.52M | 1.52M |
Hertz Announces Consent Solicitations to Amend its 12.625% First Lien Senior Secured Notes Due 2029 and 8.000% Exchangeable Senior Second-Lien PIK Notes due 2029
ESTERO, Fla. , Dec. 5, 2024 /PRNewswire/ -- Hertz Global Holdings, Inc. (NASDAQ: HTZ) ("Hertz" or the "Company"), a leading global rental car company, today announced that its wholly-owned indirect subsidiary, The Hertz Corporation ("Hertz Corp."), will solicit consents ("Consents")...
KIDPIK Reports Third Quarter 2024 Financial Results
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Kidpik Corp. ("KIDPIK" or the "Company"), an online clothing subscription-based e-commerce company, today reported its financial results for the third quarter 2024 ended September 28, 2024. Third Quarter 2024 Highlights:...
Shareholder Alert: Ademi LLP continues to investigate whether Kidpik Corp. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Kidpik (Nasdaq: PIK) for possible breaches of fiduciary duty and other violations of law in its transaction with Nina Footwear. Click here to learn how to join our investigation and obtain additional information or contact...
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kidpik Corp. – PIK
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kidpik Corp. – PIK
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
FDA Approves Genentech's Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of...
FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application and granted Priority Review to inavolisib, an...
FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with...
KIDPIK Reports First Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Kidpik Corp. (“KIDPIK” or the “Company”), an online clothing subscription-based e-commerce company, today reported its financial results for the first quarter 2024 ended March 30, 2024. First Quarter 2024 Highlights: Revenue, net: was $2.2 million, a year over...
KIDPIK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kidpik Corp. - PIK
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kidpik Corp. (the “Company”) (NasdaqCM: PIK) and Nina Footwear Corp. Upon...
Source: https://incomestatements.info
Category: Stock Reports